問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taipei Veterans General Hospital (非在職)

Division of Neurology

更新時間：2023-09-19

傅中玲Fuh, Jong-Ling
  • Principal Investigator
  • Clinical Trial Experience (year) 22 years 9 個月

Recruiting Trial

13Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

傅中玲

List

32Cases

2019-08-19 - 2024-04-30

Phase III

Completed
A 12-week phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of once monthly subcutaneous erenumab 70 mg in adult chronic migraine patients

  • Condition/Disease

    Chronic Migraine

  • Test Drug

    AMG334 (erenumab)

Participate Sites
9Sites

Recruiting2Sites

Terminated7Sites

林剛旭
China Medical University Hospital

2021-05-18 - 2026-08-21

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2025-09-01 - 2029-07-16

Phase III

Active
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease

  • Condition/Disease

    Alzheimer Disease

  • Test Drug

    Capsules

Participate Sites
5Sites

Recruiting5Sites

2023-04-01 - 2026-12-31

Others

Active

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2016-02-01 - 2020-04-02

Phase III

A Phase 3, randomized, double-blind, placebo-controlled study to evaluate LY2951742 in patients with chronic migraine — the REGAIN trial.

  • Condition/Disease

    Chronic migraine

  • Test Drug

    LY2951742

Participate Sites
5Sites

Terminated5Sites

2013-05-20 - 2018-12-31

Phase III

A multicenter, double-blind, placebo-controlled, randomised, parallel-group phase 3 study to evaluate the safety and efficacy of masitinib in patients with mild to moderate Alzheimer’s disease.

  • Condition/Disease

    mild to moderate Alzheimer’s disease

  • Test Drug

    masitinib

Participate Sites
6Sites

Terminated6Sites

2024-06-01 - 2026-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Not yet recruiting1Sites

2008-03-06 - 2009-02-20

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2019-08-01 - 2022-07-31

Phase II

A noval tau tracer ([ 18F]PM-PBB3) in young onset dementia: clinical and neuroimaging study

  • Condition/Disease

    *PRESENILE DEMENTIA;SENILE DEMENTIA, UNCOMPLICATED;DEMENTIA IN CONDITIONS CLASSIFIED ELSEWHERE;AMNESTIC  SYNDROME

  • Test Drug

    (1)[F18] AV-45 (2) [F-18] PM-PBB3

Participate Sites
3Sites

Recruiting3Sites

2019-01-01 - 2022-01-01

Others

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

1 2 3 4
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB